Social aspects of psychoactive drugs

• US Cannabis Regulation: What It Means for Naturopathic Doctors (30 Sep 2024)
  
• The Void in Clinician Counseling of Cannabis Use (24 Sep 2024)
  
• Health considerations of the legalization of cannabis edibles (24 Sep 2024)
  
• MOESM4 of Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews (23 Sep 2024)
  
• New Zealand’s Cannabis Legalisation and Control Bill: a viable approach to drug law reform (17 Sep 2024)
  
• Subgroup trends in alcohol and cannabis co-use and related harms during the rollout of recreational cannabis legalization in Washington state (16 Sep 2024)
  
• How high: differences in the developments of cannabis markets in two legalized states (16 Sep 2024)
  
• Can prescribed medical cannabis use reduce the use of other more harmful drugs? (16 Sep 2024)
  
• A Brief History of Cannabis and the Drug Conventions (16 Sep 2024)
  
• Lessons for cannabinoid regulation from electronic nicotine delivery system product regulation (03 Sep 2024)
  
• An answered call for aid? Cannabinoid clinical framework for the opioid epidemic (02 Sep 2024)
  
• Cannabis and Cancer, Part 1: Despite Lack of Evidence, Cannabis Products Being Widely Used (21 Jul 2022)
  
• What is Cannabichromene (CBC)? Benefits, Uses, Dosages (18 Jul 2022)
  
• Cannabidiol (CBD) in cannabis does not impair driving, landmark study shows (18 Jul 2022)